GlassScriptPhysician profile
Rodrigo Alfaro
NPI 1942464151
$25,077.82
in general payments reported to CMS, 2019-2025
24 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $253 · 2021: $236 · 2022: $8,970 · 2023: $7,898 · 2024: $4,832 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $2,286 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,050.00 |
| Food and Beverage | $2,286.46 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22,885.79 | 2020-2025 | Lokelma, Farxiga |
| Amgen INC. | $301.58 | 2019-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $262.01 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $225.16 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $219.57 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $200.48 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $127.51 | 2024-2025 | |
| Travere Therapeutics, INC. | $122.00 | 2023-2025 | |
| Nxstage Medical, INC. | $118.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $94.08 | 2020 | |
| Fresenius USA Marketing, INC. | $85.10 | 2023-2024 | Velphoro |
| Opko Pharmaceuticals, LLC | $72.26 | 2021-2025 | Rayaldee |
| Horizon Therapeutics Plc | $64.17 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.84 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $44.02 | 2021-2025 | Benlysta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $35.91 | 2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $33.52 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.02 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.57 | 2023 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $15.77 | 2020 | |
| Scpharmaceuticals INC. | $15.19 | 2025 | |
| Aurinia Pharma U.S., INC. | $14.63 | 2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Alfaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.